insight
✂️ 성형 🏥 중증 탈모 한방 반려 게놈 🌐 전체
← 뒤로

A new look at the 5alpha-reductase inhibitor finasteride.

🦱 탈모
4/5 보강
CNS drug reviews 2006 Vol.12(1) p. 53-76 피인용 15회 cited 174 OA RCR 4.80 Hormonal and reproductive studies
TL;DR The data suggest that endogenous neuroactive steroid levels may be inversely related to symptoms of premenstrual and postpartum dysphoric disorder, catamenial epilepsy, depression, and alcohol withdrawal.
Retraction 확인
출처
PubMed DOI PMC OpenAlex Semantic 마지막 보강 2026-05-12

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
clinical approval for the treatment of human benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern hair loss)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Results of some preclinical studies and clinical observations with finasteride are described in this review article. The data suggest that endogenous neuroactive steroid levels may be inversely related to symptoms of premenstrual and postpartum dysphoric disorder, catamenial epilepsy, depression, and alcohol withdrawal.
📑 코퍼스 인용 관계 · 인용됨 15
📑 인용한 논문 (6) ▾
연도별 인용 (2012–2026) · 합계 135
OpenAlex 토픽 · Hormonal and reproductive studies Urinary Bladder and Prostate Research Sexual function and dysfunction studies

Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE

📖 무료 전문 🟢 PMC 전문 PMC6741762 🔓 OA PDF oa
PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

Abstract

Finasteride is the first 5alpha-reductase inhibitor that received clinical approval for the treatment of human benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern hair loss). These clinical applications are based on the ability of finasteride to inhibit the Type II isoform of the 5alpha-reductase enzyme, which is the predominant form in human prostate and hair follicles, and the concomitant reduction of testosterone to dihydrotestosterone (DHT). In addition to catalyzing the rate-limiting step in the reduction of testosterone, both isoforms of the 5alpha-reductase enzyme are responsible for the reduction of progesterone and deoxycorticosterone to dihydroprogesterone (DHP) and dihydrodeoxycorticosterone (DHDOC), respectively. Recent preclinical data indicate that the subsequent 3alpha-reduction of DHT, DHP and DHDOC produces steroid metabolites with rapid non-genomic effects on brain function and behavior, primarily via an enhancement of gamma-aminobutyric acid (GABA)ergic inhibitory neurotransmission. Consistent with their ability to enhance the action of GABA at GABA(A) receptors, these steroid derivatives (termed neuroactive steroids) possess anticonvulsant, antidepressant and anxiolytic effects in addition to altering aspects of sexual- and alcohol-related behaviors. Thus, finasteride, which inhibits both isoforms of 5alpha-reductase in rodents, has been used as a tool to manipulate neuroactive steroid levels and determine the impact on behavior. Results of some preclinical studies and clinical observations with finasteride are described in this review article. The data suggest that endogenous neuroactive steroid levels may be inversely related to symptoms of premenstrual and postpartum dysphoric disorder, catamenial epilepsy, depression, and alcohol withdrawal.
📝 환자 설명용 한 줄

The data suggest that endogenous neuroactive steroid levels may be inversely related to symptoms of premenstrual and postpartum dysphoric disorder, catamenial epilepsy, depression, and alcohol withdra

이 논문을 인용하기

↓ .bib ↓ .ris
APA 7 Finn, D. A., Beadles-Bohling, A. S., Beckley, E. H., Ford, M. M., Gililland, K. R., Gorin-Meyer, R. E., & Wiren, K. M. (2006). A new look at the 5alpha-reductase inhibitor finasteride.. CNS drug reviews, 12(1), 53-76. https://doi.org/10.1111/j.1527-3458.2006.00053.x
Vancouver Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, et al. A new look at the 5alpha-reductase inhibitor finasteride. CNS drug reviews. 2006;12(1):53-76. doi:10.1111/j.1527-3458.2006.00053.x
AMA 11 Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, et al. A new look at the 5alpha-reductase inhibitor finasteride. CNS drug reviews. 2006;12(1):53-76. doi:10.1111/j.1527-3458.2006.00053.x
Chicago Finn, D. A., Beadles-Bohling, A. S., Beckley, E. H., Ford, M. M., Gililland, K. R., Gorin-Meyer, R. E., and Wiren, K. M.. 2006. "A new look at the 5alpha-reductase inhibitor finasteride." CNS drug reviews 12 (1): 53-76. https://doi.org/10.1111/j.1527-3458.2006.00053.x
MLA 9 Finn, D. A., et al. "A new look at the 5alpha-reductase inhibitor finasteride." CNS drug reviews, vol. 12, no. 1, 2006, pp. 53-76. doi:10.1111/j.1527-3458.2006.00053.x.
PMID 16834758 ↗
DOI 10.1111/j.1527-3458.2006.00053.x

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

인용 관계

그래프 OA 노드: 7/8 (88%) · 참조 0편 · 후속 7편

이 논문을 인용한 후속 연구 15

같은 제1저자의 인용 많은 논문 (2)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기